Genzyme Corporate Research Search Genzyme Websites
Gaucher Disease Treatment Information for Parents and FamiliesGaucher Disease Treatment Information for Health Care Providers
Return to Home Page


Search

Health Care Professionals
Disease Information
About Cerezyme
Cerezyme Profile
Clinical Responses to ERT
Administering Cerezyme
Monitoring
Talking with Patients
Safety
Disease Management
Ordering & Billing
Resources & Support
Prescribing Information (PDF)

Administering Cerezyme

Cerezyme® (imiglucerase for injection) is administered by intravenous infusion over 1 to 2 hours. Dosage should be individualized to each patient. Initial dosages range from 2.5 units/kg of body weight 3 times a week to 60 units/kg once every 2 weeks. 60 units/kg every 2 weeks is the dosage for which the most data are available.[1]

For more information about Cerezyme therapy and dosing, please see the full product information (PDF).

Administration support materials

To review the steps required to prepare and administer Cerezyme, you may order the Cerezyme Reconstitution and Administration (R&A) guide and video, which offer complete instructions for these procedures.

Download a PDF copy of the Reconstitution & Administration Guide.

To view PDFs, you must have Adobe Acrobat® Reader®. To download this software for free, click here.

Go to Request Materials to order the printed guide and video.

To enhance patient convenience and aid therapeutic compliance, Genzyme offers an Infusion Scheduler tool that can assist the treating physician in outlining a schedule for patients to track infusions.

Important Safety Information

Approximately 15% of patients have developed immune responses (antibodies). These patients have a higher risk of an allergic reaction (hypersensitivity). Use Cerezyme® (imiglucerase for injection) carefully if you have had an allergic reaction to the product in the past. Symptoms suggestive of allergic reaction happened in 6.6% of patients, and include anaphylactoid reaction (a serious allergic reaction), itching, flushing, hives, an accumulation of fluid under the skin, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), and low blood pressure. Side effects related to Cerezyme administration have been reported in less than 15% of patients. Each of the following events occurred in less than 2% of the total patient population. Reported side effects include nausea, vomiting, abdominal pain, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and rapid heart rate. Because Cerezyme therapy is administered by intravenous infusion, reactions at the site of injection may occur: discomfort, itching, burning, swelling or uninfected abscess. Cerezyme is available by prescription only. For more information, consult your physician. To learn more, please see full product information (PDF), or contact Genzyme at 1-800-745-4447.




References

1. Prescribing Information for Cerezyme® (imiglucerase for injection).


Highlights
Did You Know...
Gaucher disease is an autosomal recessive disorder defined by the presence of two mutant alleles for the glucocerebrosidase gene.

Resources
The Gaucher Registry is the world's largest cooperative observational study on Gaucher disease.
Learn more about participating in the registry
.

Contact Information
Genzyme Therapeutics
500 Kendall Street
Cambridge, MA 02142

800-745-4447
617-768-9000

Contact Genzyme